Compare · GLP-1 agonist
Ecnoglutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Semaglutide | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be "cAMP-biased," a real and characterized pharmacological…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.